Buy INAB by Nov 4, 2026.

DD (Due Diligence) – IN8bio Inc. (NASDAQ: INAB) A High-Risk / High-Reward Immuno-Oncology Opportunity Investment Thesis IN8bio is a clinical-stage biotechnology company developing next-generation cancer immunotherapies based on gamma-delta (γδ) T cells. The company is targeting one of the biggest opportunities in oncology: creating immune cell therapies that can recognize and eliminate cancer cells while potentially overcoming limitations seen with traditional CAR-T therapies. The current valuation reflects a highly distressed small-cap biotech, but the underlying technology has the potential to …